Health committee  Yes, it actually is defined as a rare disease.

Health committee  This is the rarest form of pulmonary—

Health committee  That would not be my area of expertise, but we'd be happy to follow up for you.

Health committee  The reality is that we do put patients first. We will do everything to try to make things available, and they will become available. The timing of such a decision may potentially be affected, though, because we are a global organization, and there will be countries that will have

Health committee  I wish I could. Unfortunately, I don't have the in-depth knowledge about what goes into our clinical trials. First of all, let me just say I hope that your children are doing well living with the rare disease. I hope that innovations have been able to give them a quality of life

Health committee  I actually don't have that information, but I'd be happy to follow up.

Health committee  Absolutely.

Health committee  It is a difficult issue to understand, and admittedly it took all of us in the community who are not health economists a while. I don't profess to be a health economist. My background is certainly coming up through the pharmaceutical organization. What we understood going forwa

Health committee  I don't think they're artificially high. There are two things. One, we are heavily regulated to ensure non-excessive pricing. There is the PMPRB, of course, and that is the list price. We also have the opportunity to negotiate. As many of you are aware, we have confidential lis

Health committee  Public plans don't list drugs as quickly, nor do they have the breadth of what private plans list for employees who are afforded that opportunity to get them through their employer. The mix is actually making sure that we have availability today. Thus, a future pharmacare progr

Health committee  Thank you so much.

Health committee  Johnson & Johnson is actually bound by our credo. It really helps us with every single decision that we make. Our credo puts patients, as well as doctors and nurses and mothers and fathers, at the core of everything we do. That's our guidepost for everything that we look to d

Health committee  Thank you. Honourable members, I would like to thank the committee for inviting me here today to speak with you regarding your study into barriers to access to treatment and drugs for Canadians affected by rare disorders. As I begin, I would like to share a bit of background as